The Marker State Space (MSS) Method for Classifying Clinical Samples

• Brian P. Fallon,

  Affiliation Laboratory of Cancer Immunodiagnostics, Van Andel Institute, Grand Rapids, Michigan, United States of America

  ⨯
• Bryan Curnutte,

  Affiliation Laboratory of Cancer Immunodiagnostics, Van Andel Institute, Grand Rapids, Michigan, United States of America

  ⨯
• Kevin A. Maupin,

  Affiliation Laboratory of Cancer Immunodiagnostics, Van Andel Institute, Grand Rapids, Michigan, United States of America

  ⨯
• Katie Partyka,

  Affiliation Laboratory of Cancer Immunodiagnostics, Van Andel Institute, Grand Rapids, Michigan, United States of America

  ⨯
• Sunguk Choi,

  Affiliation Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Randall E. Brand,

  Affiliation University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Christopher J. Langmead,

  Affiliation Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Waibhav Tembe,

  Affiliation Translational Genomics Research Institute, Phoenix, Arizona, United States of America

  ⨯
• Brian B. Haab

  * E-mail: Brian.haab@vai.org

  Affiliation Laboratory of Cancer Immunodiagnostics, Van Andel Institute, Grand Rapids, Michigan, United States of America

  ⨯